Clinical Trial Update: An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread. [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating BMS-986156 alone or with nivolumab in patients with solid tumors; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• BMS-986156
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-03-06